Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1611 1614 1628
This examiner grants 54% of resolved cases
Craig D. Ricci is a highly experienced examiner in Tech Center 1600 and Art Unit 1611, having handled 1155 resolved cases. His allowance rate of 53.5 percent reflects a balanced prosecution environment where roughly half of the applications reach a grant. This 53.5 percent rate suggests that practitioners must be prepared for substantive negotiations to overcome rejections.
A critical data point for strategy is the interview lift of 52.6 percent. This 52.6 percent increase in the probability of allowance following an interview is exceptionally high, indicating that direct engagement is one of the most effective tools for success with this examiner. Given the 1155 resolved cases on record, this lift is a statistically significant indicator of the value of oral advocacy.
The median days to allowance for this examiner is 1190. This 1190 day timeline represents the typical duration for successful prosecution in Art Unit 1611. By combining the interview lift with a proactive approach, applicants may be able to navigate the process more effectively and improve their chances beyond the baseline allowance rate.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 19171111 | SMALL MOLECULE INHIBITORS OF INTERLEUKIN-4 AND USES THEREOF | Final Rejection | Trustees of Boston University |
| 19417018 | SODIUM CHLORITE COMPOSITIONS WITH ENHANCED ANTI-MICROBIAL EFFICACY AND REDUCED TOXICITY | Non-Final OA | Allergan, Inc. |
| 18317725 | METHODS OF TREATING HEAVY MENSTRUAL BLEEDING | Non-Final OA | AbbVie Inc. |
| 17325900 | METHODS OF TREATING HEAVY MENSTRUAL BLEEDING | Non-Final OA | AbbVie Inc. |
| 18040858 | IMAGING AND TARGETING PROGRAMMED DEATH LIGAND-1 (PD-L1) EXPRESSION | Final Rejection | The Johns Hopkins University |
| 18853643 | Indolium Compounds for Treating Cancer | Non-Final OA | Emory University |
| 17596779 | COMPOSITIONS AND METHODS USING THYMOL AND/OR CARVACROL FOR INDUCTION OF AUTOPHAGY | Final Rejection | SOCIETE DES PRODUITS NESTLE S.A. |
| 18801075 | PARTICLES WITH COVALENTLY LIPID-BOUND IMMUNOSTIMULATORY AGENTS | Final Rejection | Massachusetts Institute of Technology |
| 18785975 | HYDROPHILIC LINKERS FOR ANTIBODY DRUG CONJUGATES | Non-Final OA | REGENERON PHARMACEUTICALS, INC. |
| 18719765 | CDK9 INHIBITOR AND USE THEREOF | Non-Final OA | TEIJIN PHARMA LIMITED |
| 18706144 | HETEROCYCLIC COMPOUNDS AS STING ANTAGONISTS | Non-Final OA | Boehringer Ingelheim International GmbH |
| 18653975 | USE OF QUINAZOLINONE COMPOUND FOR THE TREATMENT OF CANCER | Non-Final OA | Hoffmann-La Roche Inc. |
| 18141086 | PHARMACEUTICAL COMPOSITION FOR ADMINISTRATION AS OPHTHALMIC DROP TO PATIENT REQUIRING OPTIC NERVE PROTECTION | Non-Final OA | AJOU UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION |
| 17998204 | PHARMACEUTICAL FORMULATIONS OF ABIRATERONE ACETATE AND NIRAPARIB | Final Rejection | Janssen Pharmaceutica NV |
| 18728162 | PHARMACEUTICAL COMPOSITION COMPRISING NEUROKININ-1 ANTAGONIST PRODRUG COMPOUND | Non-Final OA | JIANGSU HENGRUI PHARMACEUTICALS CO., LTD. |
| 18683535 | FREEZE-DRYING OF LIPID NANOPARTICLES (LNPS) ENCAPSULATING RNA AND FORMULATIONS THEREOF | Non-Final OA | GLAXOSMITHKLINE BIOLOGICALS SA |
| 17717691 | Increasing Drug Bioavailability In Naltrexone Therapy | Final Rejection | Nalpropion Pharmaceuticals LLC |
| 18257272 | CRYSTALLINE FORM OF A PHENOLIC TRPV1 AGONIST PRODRUG | Non-Final OA | VP Asset Holdings LLC |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy